NCT05823402View on ClinicalTrials.gov

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

NAUnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DIAGNOSTIC_TEST

SPECT/CT

SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.

Trial Locations (1)

49503

RECRUITING

BAMF Health, Grand Rapids

Sponsors

Lead Sponsor

BAMF Health
All Listed Sponsors
lead

BAMF Health

OTHER

NCT05823402 - Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) | Biotech Hunter | Biotech Hunter